HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD. Financials Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.85 CNY | -1.83% |
|
+4.34% | +10.37% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9,293 | 7,389 | 7,091 | 7,770 | - | - |
| Enterprise Value (EV) 1 | 9,293 | 7,389 | 7,091 | 7,770 | 7,770 | 7,770 |
| P/E ratio | 62.7 x | 38.2 x | 25.9 x | 20.7 x | 15.2 x | 11.7 x |
| Yield | - | 1.17% | 0.46% | 1.58% | 1.69% | 2.78% |
| Capitalization / Revenue | - | 12.2 x | 6.97 x | 5.7 x | 4.43 x | 3.35 x |
| EV / Revenue | - | 12.2 x | 6.97 x | 5.7 x | 4.43 x | 3.35 x |
| EV / EBITDA | - | 32.2 x | 18.2 x | 15 x | 11.8 x | 8.92 x |
| EV / FCF | - | - | -11.9 x | -57.6 x | -28.9 x | -64.8 x |
| FCF Yield | - | - | -8.43% | -1.74% | -3.46% | -1.54% |
| Price to Book | - | 2.98 x | 2.64 x | 2.6 x | 2.32 x | 2.02 x |
| Nbr of stocks (in thousands) | 108,167 | 108,167 | 108,920 | 108,143 | - | - |
| Reference price 2 | 85.91 | 68.31 | 65.10 | 71.85 | 71.85 | 71.85 |
| Announcement Date | 3/14/22 | 3/12/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 607.4 | 1,017 | 1,363 | 1,754 | 2,319 |
| EBITDA 1 | - | 229.2 | 388.8 | 519 | 656.3 | 871.5 |
| EBIT 1 | - | 188.6 | 297 | 402.5 | 545.8 | 711.7 |
| Operating Margin | - | 31.06% | 29.19% | 29.54% | 31.11% | 30.68% |
| Earnings before Tax (EBT) 1 | - | 190.9 | 295.7 | 403 | 546.2 | 712 |
| Net income 1 | 111 | 194.2 | 272 | 377.7 | 513.3 | 666.5 |
| Net margin | - | 31.97% | 26.73% | 27.72% | 29.26% | 28.74% |
| EPS 2 | 1.370 | 1.790 | 2.510 | 3.467 | 4.720 | 6.117 |
| Free Cash Flow 1 | - | - | -597.9 | -135 | -269 | -120 |
| FCF margin | - | - | -58.77% | -9.91% | -15.34% | -5.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.8000 | 0.3000 | 1.135 | 1.217 | 2.000 |
| Announcement Date | 3/14/22 | 3/12/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -598 | -135 | -269 | -120 |
| ROE (net income / shareholders' equity) | - | 8.15% | 10.6% | 12.7% | 15.3% | 17.1% |
| ROA (Net income/ Total Assets) | - | 6.63% | - | 8.62% | 11% | 11.6% |
| Assets 1 | - | 2,927 | - | 4,382 | 4,654 | 5,751 |
| Book Value Per Share 2 | - | 23.00 | 24.60 | 27.60 | 31.00 | 35.60 |
| Cash Flow per Share 2 | - | 2.400 | 0.8300 | 4.240 | 5.520 | 6.840 |
| Capex 1 | - | 591 | 688 | 606 | 443 | 581 |
| Capex / Sales | - | 97.3% | 67.66% | 44.47% | 25.24% | 25.05% |
| Announcement Date | 3/14/22 | 3/12/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
71.85
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.37% | 1.08B | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- 301096 Stock
- Financials Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.